Inorg. Chem. 2007, 46, 3407-3418



# Pyrazole Complexes as Anion Receptors: Effects of Changing the Metal, the Pyrazole Substitution Pattern, and the Number of Pyrazole Ligands

Sonia Nieto,<sup>†</sup> Julio Pérez,<sup>\*,†</sup> Lucía Riera,<sup>\*,†</sup> Víctor Riera,<sup>†</sup> Daniel Miguel,<sup>‡</sup> James A. Golen,<sup>§</sup> and Arnold L. Rheingold<sup>§</sup>

Departamento de Química Orgánica e Inorgánica-IUQOEM, Facultad de Química, Universidad de Oviedo-CSIC, 33006 Oviedo, Spain, Departamento de Química Inorgánica, Facultad de Ciencias, Universidad de Valladolid, 47005 Valladolid, Spain, and Department of Chemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093

Received January 2, 2007

Compound  $cis, fac-[Mo(\eta^3-allyl)(CO)_2(Hdmpz)_3]BAr'_4$  (1) (Hdmpz = 3,5-dimethylpyrazole, Ar' = 3,5-bis(trifluoromethyl)phenyl) undergoes rapid substitution of one of the pyrazole ligands by anions, including the low nucleophilic ReO<sub>4</sub><sup>--</sup>, a reaction that afforded  $[Mo(OReO_3)(\eta^3-allyl)(CO)_2(Hdmpz)_2]$  (2), structurally characterized by X-ray diffraction. The new compounds fac-[Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (4a) and fac-[Mn(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]BAr'<sub>4</sub> (4b) (H'Bupz = 3(5)-tertbutylpyrazole) also undergo pyrazole substitution with most anions, and the product from the reaction with nitrate was crystallographically characterized. Compounds 4a,b were found to be substitutionally stable toward perrhenate, and the adducts [Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]•[ReO<sub>4</sub>] (7a) and [Mn(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]•[ReO<sub>4</sub>]•[Bu<sub>4</sub>N]•[BAr'<sub>4</sub>] (7b), crystallographically characterized, display hydrogen bonds between one of the perrhenate oxygens and the N-H groups of two of the pyrazole ligands. The structurally similar adduct [Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]-[ReO<sub>4</sub>] (8) was found to result from the interaction of [Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> with perrhenate. The reaction of [Re(OTf)(CO)<sub>5</sub>] with 3,5-dimethylpyrazole (Hdmpz) afforded [Re(CO)<sub>5</sub>(Hdmpz)]OTf (9). The reaction of 9 with Hdmpz and NaBAr'<sub>4</sub> yielded [Re(CO)<sub>4</sub>-(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (10), which was found to be unstable toward chloride anion. In contrast, the new compound fac, cis-[Re(CO)<sub>3</sub>(CN<sup>3</sup>Bu)(Hdmpz)<sub>2</sub>[BAr'<sub>4</sub> (11) is stable in solution in the presence of different anions. Binding constants for 11 with chloride, bromide, and nitrate are 1-2 orders of magnitude lower than those found for these anions and rhenium tris(pyrazole) hosts, indicating that the presence of the third pyrazole ligand is crucial. Compounds fac- $[Re(CO)_3(HPhpz)_3]BAr'_4$  (14) (HPhpz = 3(5)-phenylpyrazole) and fac- $[Re(CO)_3(HIndz)_3]BAr'_4$  (15) (HIndz = indazole) are, in terms of anion binding strength and selectivity, inferior to those with dimethylpyrazole or tert-butylpyrazole ligands.

## Introduction

Metals have been incorporated into the structures of supramolecular anion hosts for a variety of purposes.<sup>1</sup> Recently, it has been found that metals can serve as the major geometry-organizing element, thus allowing for a modular synthesis of the hosts, and coordination compounds with

Universidad de Oviedo-CSIC.

ligands featuring convergently arranged hydrogen-bond donor groups have begun to be used as anion receptors.<sup>2</sup>

Parkin, Reger, and Halcrow have reported the structural characterization of supramolecular adducts of the type  $[LnM(Hpz')_3]$ ····Cl (Hpz' = generic pyrazole), featuring a chloride anion hydrogen-bonded by the N-H groups of three pyrazoles, the convergent geometry of which results from their bonding to the metal- or metalloid-based LnM fragment.<sup>3</sup> Cationic metalloreceptors  $[LnM(Hpz')_3]^+$  could be

<sup>\*</sup> To whom correspondence should be addressed. E-mail: japm@ uniovi.es (J.P.); lrm@fq.uniovi.es (L.R.). Fax: (34) 985103446 (J.P.).

<sup>&</sup>lt;sup>‡</sup> Universidad de Valladolid.

<sup>§</sup> University of California.

 <sup>(1) (</sup>a) Beer, P. D.; Gale, P. A. Angew. Chem., Int. Ed. 2001, 40, 486. (b) Steed, J. W. Chem. Commun. 2006, 2637. (c) Filby, M. H.; Steed, J. W. Coord. Chem. Rev. 2006, 250, 3200.

<sup>10.1021/</sup>ic0700046 CCC: \$37.00 © 2007 American Chemical Society Published on Web 03/17/2007

<sup>(2) (</sup>a) Bondy, C. R.; Gale, P. A.; Loeb, S. J. *Chem. Commun.* 2001, 729.
(b) Wallace, K. J.; Daari, R.; Belcher, W. J.; Abouderbala, L. O.; Boutelle, M. G.; Steed, J. W. *J. Organomet. Chem.* 2003, 666, 63. (b) Bondy, C. R.; Gale, P. A.; Loeb, S. J. *J. Am. Chem. Soc.* 2004, *126*, 5030. (c) Rice, C. R. *Coord. Chem. Rev.* 2006, *250*, 3190.

**Scheme 1.** Substitution of a Hdmpz Ligand for Chloride by Addition of  $[Bu_4N][Cl]$  to a Solution of  $cis_fac$ - $[Mo(\eta^3-C_3H_5)(CO)_2(Hdmpz)_3]$  (1)



thought of as the reverse of the tris(pyrazolyl)borates and their analogues, a widely employed family of ligands.<sup>4</sup>

We have recently reported the synthesis of the octahedral fac-[Re(CO)<sub>3</sub>(Hpz')<sub>3</sub>]BAr'<sub>4</sub> compounds and the study of their behavior toward anions, both in solution and in the solid state.<sup>5</sup> These compounds constitute a new class of transition metal-based supramolecular anion receptors where the geometrical preferences of the metal are taken advantage of to organize the ditopic pyrazole molecules such that their N-H groups can converge toward an external anion. Distinctive features of our receptors are the fac geometry of the pyrazoles and the employment of the BAr'<sub>4</sub><sup>-</sup> (Ar' = 3,5-bis(trifluoromethyl)phenyl) counteranion, with a high delocalization of the negative charge. In the studies carried out so far,<sup>5</sup> we have found that, both in solution and in the solid state (for the nitrate anion), two out of the three pyrazoles are the ones that simultaneously form hydrogen bonds with anions, and we have attributed this feature to the reluctance of our complexes to distort the L-M-L angles. We set out to complete these investigations, including structural studies of adducts with other anions as well as the behavior of other cationic octahedral fac-tris(pyrazole) transition metal complexes. Our results in this area are the matter of the present contribution.

#### **Results and Discussion**

Metals Other Than Rhenium. Molybdenum and Manganese Complexes. We have recently prepared the compound *cis,fac*-[Mo( $\eta^3$ -allyl)(CO)<sub>2</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (1) (Hdmpz = 3,5-dimethylpyrazole), the structural characterization of which confirmed the *fac* disposition of the three pyrazole ligands.<sup>6</sup> This compound was chosen to study its behavior as an anion receptor because, in contrast to the majority of Mo(II) carbonyl complexes,<sup>7</sup> most pseudooctahedral molybdenum allyl dicarbonyl complexes with two coordination sites occupied by nitrogen-donor ligands are structurally rigid in solution.<sup>8</sup> Indeed, solution spectroscopic studies showed that the structure of the cationic complex of **1** is rigid and that no fast pyrazole exchange was taking place. In addition, complexes containing the {Mo( $\eta^3$ -allyl)(CO)<sub>2</sub>} fragment do not need to be handled under strictly air- and moisture-free conditions.<sup>9</sup>

The addition of the equimolar amount of tetrabutylammonium chloride to a CH<sub>2</sub>Cl<sub>2</sub> solution of 1 led to the almost instantaneous formation of a new species with IR  $\nu$ (CO) bands at 1939 and 1837 cm<sup>-1</sup>, significantly lower than those found for **1** (1951 and 1863  $\text{cm}^{-1}$ ) and closely similar to those found for the neutral complex  $[MoBr(\eta^3-allyl)(CO)_2-$ (Hdmpz)<sub>2</sub>], recently reported by Villafañe and co-workers (1942 and 1843 cm<sup>-1</sup>).<sup>10</sup> In fact, the new bands were found to correspond to the complex  $[MoCl(\eta^3-allyl)(CO)_2(Hdmpz)_2]$ (2), independently prepared as depicted in Scheme 1 and detailed in the Experimental Section. The <sup>1</sup>H NMR spectrum of the chloro complex indicates the presence of two nonequivalent pyrazole ligands, consistent with the asymmetric structure displayed in Scheme 1 and similar to the one demonstrated by X-ray diffraction for [MoBr( $\eta^3$ -allyl)(CO)<sub>2</sub>- $(Hdmpz)_{2}]^{10}$ 

Perrhenate, an anion much less nucleophilic than chloride, also effects the substitution of one of the pyrazoles in **1**. The product, complex [Mo(OReO<sub>3</sub>)( $\eta^3$ -allyl)(CO)<sub>2</sub>(Hdmpz)<sub>2</sub>] (**3**), was characterized by X-ray diffraction (see Figure 1). Although of poor quality, the results of the crystallographic analysis establish that its pseudooctahedral molecule consists of two Hdmpz ligands and a monodentate ReO<sub>4</sub><sup>-</sup> ligand

- (7) Baker, P. K. Adv. Organomet. Chem. 1995, 40, 45.
- (8) Pérez, J.; Riera, L.; Riera, V.; García-Granda, S.; García-Rodríguez, E. J. Am. Chem. Soc. 2001, 123, 7469.
- (9) Morales, D.; Navarro Clemente, M. E.; Pérez, J.; Riera, L.; Riera, V.; Miguel, D. Organometallics 2002, 21, 4934.
- (10) Paredes, P.; Miguel, D.; Villafañe, F. Eur. J. Inorg. Chem. 2003, 995.

<sup>(3) (</sup>a) Looney, A.; Parkin, G.; Rheingold, A. L. *Inorg. Chem.* 1991, *30*, 3099. (b) Reger, D. L. Ding, Y.; Rheingold, A. L. Ostrander *Inorg. Chem.* 1994, *33*, 4226. (c) Liu, X.; Kilner, Colin A.; Halcrow, M. A. *Chem. Commun.* 2002, 704. (d) Renard, S. L.; Kilner, C. A.; Fisher, J.; Halcrow, M. A. *Dalton Trans.* 2002, 4206.

<sup>(4)</sup> Trofimenko, S. Polyhedron 2004, 23, 193.

<sup>(5) (</sup>a) Nieto, S.; Pérez, J.; Riera, V.; Miguel, D.; Alvarez, C. Chem. Commun. 2005, 546. (b) Nieto, S.; Pérez, J.; Riera, L.; Riera, V.; Miguel, D. Chem.—Eur. J. 2006, 12, 2244.

<sup>(6)</sup> Pérez, J.; Morales, D.; Nieto, S.; Riera, L.; Riera, V.; Miguel, D. Dalton Trans. 2005, 884.



**Figure 1.** Thermal ellipsoid (30%) plot of *cis,cis*-[Mo(OReO<sub>3</sub>)( $\eta^3$ -allyl)(CO)<sub>2</sub>(Hdmpz)<sub>2</sub>] (3).

**Scheme 2.** Synthesis of the Potential New Receptors *fac*-[Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (**4a**) and *fac*-[Mn(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]BAr'<sub>4</sub> (**4b**)



coordinated to an unremarkable *cis*-{Mo( $\eta^3$ -allyl)(CO)<sub>2</sub>} fragment. One of the pyrazole ligands is *trans* to the allyl group, and the other is *trans* to one of the carbonyls, so that the resulting asymmetric geometry is similar to that previously encountered for [MoBr( $\eta^3$ -allyl)(CO)<sub>2</sub>(Hdmpz)<sub>2</sub>].<sup>10</sup> IR and <sup>1</sup>H NMR spectroscopies indicate that this structure is maintained in solution.

The results discussed above indicate that, due to the lability of the pyrazole ligands in compound  $[Mo(\eta^3-allyl)-(CO)_2(Hdmpz)_3]BAr'_4$  (1), this cannot be used as an anion receptor.

We next turned our attention to manganese compounds. The structural chemistry of Mn(I) carbonyl complexes is closely related to that of Re(I), the latter species being the ones that we initially found to be stable anion receptors.<sup>5</sup> Compounds *fac*-[Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (**4a**) and *fac*-[Mn(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]BAr'<sub>4</sub> (**4b**) could be readily synthesized by a method similar to the one previously employed for the synthesis of the rhenium analogues (see Scheme 2 and Experimental Section). These new compounds were characterized in solution by spectroscopy (see Experimental Section) and in the solid-state by X-ray diffraction (see Figure 2). Pyrazole complexes of Mn(I) carbonyl fragments are rare, and in only a few examples X-ray structural data are available.<sup>11</sup>



**Figure 2.** (a) Thermal ellipsoid (30%) plot of fac-[Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]-BAr'<sub>4</sub> (**4a**). (b) Thermal ellipsoid (30%) plot of fac-[Mn(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]-BAr'<sub>4</sub> (**4b**).

As expected, like their rhenium congeners, the new cationic complexes present in **4a**,**b** have pseudooctahedral geometry and a *fac* disposition of the three pyrazole ligands, both in solution (as indicated by the *fac*-tricarbonyl pattern of the  $\nu$ (CO) bands in the IR spectra and by the presence of a single set of pyrazole signals in the <sup>1</sup>H NMR spectra) and in the solid state.

The reactions of **4a**,**b** with the equimolar amount of tetrabutylammonium chloride in dichloromethane afforded the products of the substitution of one of the pyrazole ligands by chloride, namely, the neutral compounds *fac*-[MnCl(CO)<sub>3</sub>-(Hdmpz)<sub>2</sub>] (**5a**) and *fac*-[MnCl(CO)<sub>3</sub>(H'Bupz)<sub>2</sub>] (**5b**) (see Scheme 3 and Experimental Section). These compounds are closely similar to the manganese complexes recently reported by Villafañe and co-workers.<sup>11</sup> Most of the less nucleophilic anions also led to pyrazole displacement, as judged by the

<sup>(11)</sup> Arroyo, M.; Lopez-Sanvicente, A.; Miguel, D.; Villafañe, F. Eur. J. Inorg. Chem. 2005, 4430.

Scheme 3. Synthesis of fac-[MnCl(CO)<sub>3</sub>(Hpz')<sub>2</sub>] (5a,b) Complexes: Straightforward or by Substitution of an Pyrazole Ligand for Chloride Anion



shift to significantly lower wavenumber values, typical of neutral fac-[MnX(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>] complexes, in the IR  $\nu$ (CO) bands. In particular, this was conclusively demonstrated for the nitrate anion. Thus, the product of the reaction of **4a** with tetrabutylammonium nitrate was isolated and its structure was determined by X-ray diffraction. The results showed that the product is an adduct in which noncoordinated 3,5-dimethylpyrazole (resulting from its displacement by the nitrate anion out of the first metal coordination sphere) interacts only through hydrogen bonds with the new complex fac, *cis*-[Mn(ONO<sub>2</sub>)(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>] (**6**), featuring a monodentate nitrato ligand (see Figure 3).

The main hydrogen bond interactions in the [**6**]·[Hdmpz] adduct are shown as dotted lines in Figure 3. The N–H group of the second-sphere pyrazole acts as hydrogen bond donor toward two of the oxygen atoms of the nitrato ligand  $(O(5)\cdots N(8) = 3.283(4) \text{ Å}, H(8)\cdots O(5) = 2.427 \text{ Å}, N(8)\cdots$  $H(8)\cdots O(5) = 174.9(3)^{\circ}; O(4)\cdots N(8) = 3.270(4) \text{ Å}, H(8)\cdots$  $O(4) = 2.695 \text{ Å}, N(8)\cdots H(8)\cdots O(4) = 125.6(3)^{\circ})$ , and its pyridine-type nitrogen acts as hydrogen bond acceptor toward the N–H group of one of the pyrazole ligands  $(N(2)\cdots N(7) = 2.904(4) \text{ Å}, H(2)\cdots N(7) = 1.947 \text{ Å}, N(2)\cdots H(2)\cdots N(7)$ 



**Figure 3.** Thermal ellipsoid (30%) plot of the adduct *fac,cis*-[Mn(ONO<sub>2</sub>)-(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>] (**6**) with Hdmpz. Selected distances (Å) and angles (deg) for **6**: O(5)···N(8) 3.283(4), H(8)···O(5) 2.427; N(8)···H(8)···O(5) 174.9(3), O(4)···N(8) 3.270(4), H(8)···O(4) 2.695, N(8)···H(8)···O(4) 125.6(3), N(2)···N(7) 2.904(4), H(2)···N(7) 1.947, N(2)···H(2)···N(7) 163.3(3), N(4)···O(4) 2.871(4), H(4)···O(4) 2.515, N(4)···H(4)···O(4) 107.6(2).

3410 Inorganic Chemistry, Vol. 46, No. 8, 2007

=  $163.3(3)^{\circ}$ ). In addition, there is an interligand nitratopyrazole hydrogen bond (N(4)····O(4) = 2.871(4) Å, H(4)····O(4) = 2.515 Å; N(4)····H(4)····O(4) =  $107.6(2)^{\circ}$ ).

Unlike the molybdenum compound 1, the manganese compounds 4a,b are stable in solution (i.e., do not undergo pyrazole substitution) in the presence of the poorly nucleophilic perrhenate anion, and the 1:1 binding constants in acetonitrile were found to be 28(1) and 22(1) M<sup>-1</sup>, respectively. Slow diffusion of hexane into a dichloromethane solution of an equimolar mixture of compound 4a and [Bu<sub>4</sub>N]-[ReO<sub>4</sub>] afforded two different types of crystals, and their <sup>1</sup>H NMR spectra showed them to have the fac-[Mn(CO)<sub>3</sub>- $(Hdmpz)_3]$ ·[ReO<sub>4</sub>] (7a) and  $[Bu_4N][BAr'_4]$  compositions. Such a segregation into two different phases has been previously found by us when using cationic receptors containing the  $BAr'_4$  counteranion together with tetrabutylammonium salts. However, a similar crystallization of an equimolar mixture of compound 4b and the salt [Bu<sub>4</sub>N]-[ReO<sub>4</sub>] yielded crystals of a single phase **7b** (see below) containing the four ions  $[Mn(CO)_3(H'Bupz)_3]^+$ ,  $[ReO_4]^-$ ,  $[Bu_4N]^+$ , and  $[BAr'_4]^-$ . Thus, changes that, at first sight, one could expect to be of little significance in the exact composition of the complexes exert a dramatic effect on the composition of the crystalline phase. This is further illustrated by the fact that the nitrate adduct of the complex fac- $[Re(CO)_3(H'Bupz)_3]^+$ , the rhenium analogue of the cation present in 4b, was found to crystallize separately from [Bu<sub>4</sub>N][BAr'<sub>4</sub>].<sup>5b</sup>

The structures of compounds **7a,b** were determined by single-crystal X-ray diffraction, and the results are displayed in Figure 4. For comparison purposes, the structure of the rhenium adduct [Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]•[ReO<sub>4</sub>] (**8**), which crystallized separately from the salt [Bu<sub>4</sub>N]•[BAr'<sub>4</sub>], was also determined, and the results are displayed in Figure 5.

Two features are common to the three structures (**7a**,**b** and **8**) and to that of fac-[Re(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]·[NO<sub>3</sub>], mentioned above and previously determined by us:<sup>5b</sup> (a) only two out of the three pyrazole ligands of each cationic complex are simultaneously forming hydrogen bonds with a given oxoanion; (b) in these hydrogen bonds a single oxygen atom of the oxoanion is acting as acceptor. Additional hydrogen bonding between the third pyrazole ligand and other oxygen atoms of the oxoanion contribute to the solid-



Figure 4. (a) Thermal ellipsoid (30%) plot of the adduct  $[Mn(CO)_3(Hdmpz)_3] \cdot [ReO_4]$  (7a). (b) Thermal ellipsoid (30%) plot of the  $[Mn(CO)_3(H'Bupz)_3] \cdot [ReO_4]$  adduct present in 7b.

state network. Since these facts occur with cationic complexes containing either Mn (**7a**,**b**) or (the substantially larger) Re (**8**) as a central atom, and both in the presence (**7b**) or absence (**7a** or **8**) of the  $[Bu_4N][BAr'_4]$  salt in the crystalline phase, it seems that they must be dictated by the geometry of the fac- $[M(CO)_3(Hpz')_3]$  (Hpz' = generic pyrazole) complexes rather than by the size or by packing factors.

**Compounds with Only Two Pyrazole Ligands.** In our previous studies with *fac*-[Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> and *fac*-[Re(CO)<sub>3</sub>(H'Bupz)<sub>3</sub>]BAr'<sub>4</sub> receptors, we have shown that, both in the solid state and in solution, the anionic guest forms simultaneously hydrogen bonds with only two of the three ligated pyrazoles.<sup>5b</sup> This is also the solid-state arrangement found in the structures discussed above.

To complete these studies, and with the goal of evaluating the effect of the presence of a third pyrazole ligand on the strength of the host-guest interaction, we set out to prepare



**Figure 5.** Thermal ellipsoid (30%) plot of the adduct [Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>] · [ReO<sub>4</sub>] (8).

Scheme 4. Synthesis of [Re(CO)<sub>4</sub>(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (10) via the Intermediate [Re(CO)<sub>5</sub>(Hdmpz)]OTf (9)



compounds of the kind *fac*,*cis*-[Re(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>(L)]BAr'<sub>4</sub> (L = neutral, two-electron donor not able to act as a good hydrogen bond donor) and compare the strength of their anion binding with that displayed by the tris(pyrazole) compounds. We first attempted to synthesize the compound [Re(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>(tmpz)]BAr'<sub>4</sub> (tmpz = 1,3,5-trimethylpyrazole), since the tmpz ligand would most closely mimic the electronic and steric profile of 3,5-dimethylpyrazole, while lacking its capability of engaging in strong hydrogen bonds. However, we could not find a synthetic pathway that would cleanly afford this compound. Similarly, attempts to prepare the [Re(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>(L)]BAr'<sub>4</sub> (L = *N*-methylimidazole) led only to mixtures that could not be resolved.

On the other hand, we could successfully prepare the compound *cis*-[Re(CO)<sub>4</sub>(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (**10**) as shown in Scheme 4. Compound **10** as well as the synthetic intermediate [Re(CO)<sub>5</sub>(Hdmpz)]OTf (**9**), both new compounds, were characterized by IR, <sup>1</sup>H NMR, and single-crystal X-ray diffraction. Thermal ellipsoid representations and selected distances and angles for compounds **9** and **10** are given in Figure 6.

The preparation and spectroscopic characterization of the pentacarbonyl pyrazole compound  $[Re(CO)_5(Hpz)]BF_4$ , closely related to **9**, has been previously reported by Beck and co-workers.<sup>12</sup>

In the solid-state structure of **9**, a hydrogen bond between the pyrazole ligand and the triflate anion is characterized by a N(2)···O(11) = 2.773(7) Å distance and a N(2)···H···O(11) = 169(5)° angle, values that suggest a relatively strong interaction. Treatment of **9** with the equimolar amount of the salt NaBAr'<sub>4</sub> in dichloromethane for a few minutes at room temperature, followed by reaction with 3,5-dimethylpyrazole in refluxing toluene, yielded *cis*-[Re(CO)<sub>4</sub>(Hdmpz)<sub>2</sub>]-BAr'<sub>4</sub> (**10**) (see Scheme 4 and Experimental Section). However, the reaction is not clean, and **10** was obtained contaminated with a second metal—carbonyl species, as shown by the IR monitoring of the reaction. Fractional crystallization afforded pure **10**, although in a low yield.

Preliminary experiments revealed that **10** is not stable toward chloride anion in solution; thus, further study of its behavior was not pursued. Likewise, the compound  $[Re(CO)_3(Hdmpz)_2(py)]BAr'_4$  (py = pyridine) turned out to be unstable toward substitution of the pyridine ligand by anions.

Fortunately, the compound fac,cis-[Re(CO)<sub>3</sub>(CN'Bu)-(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (11), prepared as summarized in Scheme



5, was found to be stable toward anions in solution (see below).

Besides its spectroscopic characterization in solution, the solid-state structure of **11** was determined by means of X-ray diffraction. The results are displayed in Figure 7.

The solution spectral data for compound **11** are consistent with a structure in solution similar to that found in the solid



**Figure 6.** (a) Molecular structure of complex  $[Re(CO)_5(Hdmpz)]OTf (9)$ . Selected distances (Å) and angles (deg) for 9:  $N(2)\cdots O(11)$  2.773(7);  $N(2)\cdots H\cdots O(11)$  169(5). (b) Molecular structure of the cation of *cis*- $[Re(CO)_4(Hdmpz)_2]$  BAr'<sub>4</sub> (10).

## Pyrazole Complexes as Anion Receptors

Scheme 5. Synthesis of Compound fac-[Re(CN/Bu)(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (11)



state. Thus, the IR spectrum in dichloromethane featured intense  $\nu$ (CO) bands at 2038, 1960, and 1940 cm<sup>-1</sup>, diagnostic of the *fac*-{Re(CO)<sub>3</sub>} fragment, and a medium intensity  $\nu$ (CN) band at 2186 cm<sup>-1</sup>, due to the isocyanide ligand. As in the tris(pyrazole) complexes discussed above, the presence of separate signals for the methyl groups in the 3 and 5 positions of the pyrazole ring indicates that the pyrazole ligands are not labile.<sup>5a</sup> The presence of a mirror plane in the molecule of **11** is reflected in the presence of only one set of pyrazole signals in the <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra and of two weak, low-field signals of different intensity, due to the two types of carbonyl ligands, in the <sup>13</sup>C NMR.

In the solid-state structure of **11**, the Re–C(isocyanide) distance, 2.078(7) Å, is only slightly longer than the Re–C(carbonyl) distances (1.926(9), 1.962(8), and 1.968(8) Å), reflecting that the isocyanide is a strong ligand, with electronic properties similar to those of carbon monoxide. The rigidity and linearity of the isocyanide ligand (Re–C(4)–N(5) = 176.8(6)° and C(4)–N(5)–C(41) = 177.1(7)°) keeps the bulky *tert*-butyl group far from the metal and from the N–H groups of the pyrazole ligands, so that its presence should not hinder the approach of the anionic guests.

Compound **11** was found to be substitutionally stable in the presence of excess of tetrabutylammonium chloride, bromide, and nitrate. Thus, in the IR spectra of such solutions, the  $\nu$ (CN) band of free *tert*-butyl isocyanide at 2140 cm<sup>-1</sup> could not be observed, and the wavenumber



**Figure 7.** Thermal ellipsoid (30%) plot of the cation  $[Re(CN'Bu)(CO)_3-(Hdmpz)_2]^+$  of compound **11**. Selected distances (Å) and angles (deg) for **11**: Re(1)-C(4) 2.078(7); Re-C(4)-N(5) 176.8(6), C(4)-N(5)-C(41) 177.1(7).

**Scheme 6.** Proposed Equilibria in Solution of Compounds *fac*-[M(CO)<sub>3</sub>(Hpz')<sub>3</sub>]BAr'<sub>4</sub> in the Presence of an External Anion



values of the  $\nu(CO)$  bands corresponding to 11 undergo only relatively minor changes to lower wavenumber values attributed to the small increase in electron density resulting from the anion hydrogen bonding. Thus, for instance, the addition of 1 equiv of chloride shifts the higher frequency  $\nu$ (CO) band from 2040 to 2032 cm<sup>-1</sup>. This change is the largest found for all the studied anions. The <sup>1</sup>H NMR spectra of the 11-[Bu<sub>4</sub>NX] mixtures did not show evidence of free 3,5-dimethylpyrazole, and the changes were found to be dependent on the amount of anion added and to be consistent with the formation of hydrogen bonds between the pyrazole N-H groups and the anion. Thus, the shift to lower field of the pyrazole N–H signals as a response to the anion addition was used to calculate the binding constants. These were found to be 75(7), 174(7), and 133(11)  $M^{-1}$  (in CD<sub>3</sub>CN) for chloride, bromide, and nitrate, respectively. These values are 1-2 orders of magnitude lower that those obtained for these anions and the receptor fac-[Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub>.<sup>5</sup> Therefore, in spite of the fact that the low-temperature <sup>1</sup>H NMR spectroscopy showed that the instantaneous solution structures are consistent with an interaction of the anionic guest with only two of the three ligated pyrazoles<sup>5b</sup> and that it is also the kind of interaction found in the solid state, the presence of a third pyrazole ligand significantly enhances the strength of the receptor-guest interaction. This cannot be explained on the basis of the different electronic properties of the pyrazole and the isocyanide as ligands. In fact, the isocyanide is a stronger acceptor than the pyrazole, and therefore, if there is any effect of the presence of either pyrazole or isocyanide as the third ligand on the N-H groups of the anion-binding pyrazoles, it should be to make stronger those hydrogen-bond donors of the isocyanide-containing complex. As mentioned above, since the bulky 'Bu group is relatively away from the N-H groups, steric hindrance does not seem an attractive explanation. Rather, we speculate that the higher binding constants for the tris(pyrazole) compounds can be attributed to the presence of three equivalent hostguest interactions of sufficient strength and which interconversion should be kinetically facile (see Scheme 6). On the other hand, we do not rule out the possibility that an additional, weaker hydrogen bond between the anion and the N-H group of the third pyrazole could account for the difference in binding constants between complexes with two or three pyrazoles.

**Different Pyrazole Ligands.** Since the geometry of the interaction between the anionic guest and the cationic  $[M(CO)_3(Hpz')_3]$  (Hpz' = generic pyrazole) host is qualitatively the same for the complexes of either 3,5-dimethyl-pyrazole or 3(5)-*tert*-butylpyrazole, we decided to investigate how the choice of different pyrazole ligands could affect the behavior of the tris(pyrazole) complexes toward anions.

Manganese and rhenium complexes of nonsubstituted pyrazole were prepared using the same simple procedure that allowed us to isolate the aforementioned derivatives of substituted pyrazole. The new compounds fac-[Mn(CO)3- $(Hpz)_3$  BAr'<sub>4</sub> (12) and fac-[Re(CO)<sub>3</sub>(Hpz)<sub>3</sub>]BAr'<sub>4</sub> (13) were spectroscopically characterized by IR and NMR. Like its dimethyl- or *tert*-butyl-substituted congeners, the manganese compound 12 was found to resist pyrazole substitution when treated with perrhenate (a 1:1 binding constant of 28(1) M<sup>-1</sup> was found for this anion in acetonitrile) but to undergo pyrazole substitution in the presence of chloride, bromide, and nitrate. Compound 13 was found to be substitutionally stable toward bromide, nitrate, and perrhenate, and binding constants of 540(27), 112(13), and 63(1) M<sup>-1</sup>, respectively, were calculated for these anions (CD<sub>3</sub>CN). However, treatment of 13 with tetrabutylammonium chloride led to substitution of one of the pyrazole ligands by chloride. This result contrasts with the stability showed by the 3,5dimethylpyrazole or the 3(5)-tert-butylpyrazole analogues. The difference can be explained by the steric protection lent by the substituents, previously noted when comparing the behavior of fac-[Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> and fac-[Re(CO)<sub>3</sub>-(H<sup>t</sup>Bupz)<sub>3</sub>]BAr'<sub>4</sub> receptors.<sup>5b</sup>

The presence of planar aromatic rings as substituents at the pyrazole ligands can give rise to stronger hydrogen bond donor N-H groups (due to the electron-withdrawing character of the aryl groups when compared with methyl or tertbutyl groups) and perhaps to a more discriminating binding cavity if the aryl groups are adequately disposed. Therefore, we set out to prepare tris(pyrazole) receptors featuring aromatic groups. Compound fac-[Re(CO)<sub>3</sub>(HPhpz)<sub>3</sub>]BAr'<sub>4</sub> (14) (HPhpz = 3(5)-phenylpyrazole) was prepared by the method used for the derivatives mentioned above and spectroscopically characterized (see Experimental Section). Compound 14 was found to be stable toward chloride, bromide, iodide, nitrate, hydrogensulfate, and perrhenate, and 1:1 binding constants of 2406(125), 1712(90), 80(1), 1592(1), 147(1), and 67(9) M<sup>-1</sup>, respectively, were calculated for these anions in deuterated acetonitrile. Albeit comparable, these values do not offer a clear advantage when compared with the behavior of fac-[Re(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> and fac- $[Re(CO)_3(H^tBupz)_3]BAr'_4$  receptors.

Indazole (HIndz) features a fused aromatic ring and thus can be regarded as a rigid phenyl-substituted pyrazole. Compound fac-[Re(CO)<sub>3</sub>(HIndz)<sub>3</sub>]BAr'<sub>4</sub> (15) (see Experimental Section for the synthesis and characterization) was found to be stable toward chloride, bromide, iodide, nitrate,

Table 1. Binding Constant Values for Compound 15 in CD<sub>3</sub>CN

	6	1	
anions	$K_{\rm a}({ m M}^{-1})$	anions	$K_{\rm a}({ m M}^{-1})$
Cl-	$320\pm 6$	$HSO_4^-$	$141 \pm 6$
$\mathrm{Br}^{-}$	$404 \pm 2$	$\text{ReO}_4^-$	$48 \pm 6$
$I^-$	$100 \pm 2$	$ClO_4^-$	$10.5 \pm 0.2$
$NO_3^-$	$295 \pm 2$		

hydrogensulfate, perrhenate, and perchlorate. Binding constants for these anions, displayed in Table 1, indicate an interaction weaker than that found for the tris(pyrazole) complexes and no selectivity. More basic anions such as fluoride and dihydrogen phosphate were found to deprotonate **15** to afford a neutral complex, as indicated by the large shift to lower wavenumber values in the IR  $\nu$ (CO) bands, a behavior also displayed by the previously reported tris-(pyrazole) complexes derived from Hdmpz or H'Bupz.<sup>5b</sup> The solid-state structures of the 1:1 adducts *fac*-[Re(CO)<sub>3</sub>-(HIndz)<sub>3</sub>]·[ReO<sub>4</sub>] (**16**) and *fac*-[Re(CO)<sub>3</sub>(HIndz)<sub>3</sub>]·[CIO<sub>4</sub>] (**17**) were determined by X-ray diffraction, and the results are shown in Figure 8.

The most revealing feature of these structures is that, unlike in the adducts of the pyrazole compounds, now only one of the N-H bonds of each cationic complex forms a



**Figure 8.** (a) Thermal ellipsoid (30%) plot of the adduct *fac*-[Re(CO)<sub>3</sub>-(HIndz)<sub>3</sub>]•[ReO<sub>4</sub>] (**16**). (b) Thermal ellipsoid (50%) plot of the adduct *fac*-[Re(CO)<sub>3</sub>(HIndz)<sub>3</sub>]•[CIO<sub>4</sub>] (**17**).

## Pyrazole Complexes as Anion Receptors

hydrogen bond to a given anion. Therefore, the main effect of the fused ring, rather than providing an extra hydrogen bond donor, seems to be hindering the anion approach. As indicated by the comparison of the binding constants (that reach higher values for the tris(phenylpyrazole) derivative), this effect must be much more pronounced for the indazole derivatives, where the benzene ring is rigidly linked to the pyrazole ring, than for the phenylpyrazole derivatives, where there must be free rotation around the phenyl-pyrazole bond.

#### Conclusion

Unlike previously reported rhenium compounds *fac*-[Re(CO)<sub>3</sub>(Hpz<sup>\*</sup>)<sub>3</sub>]BAr'<sub>4</sub> (Hpz<sup>\*</sup> = Hdmpz or H'Bupz), molybdenum and manganese cationic tris(pyrazole) hosts *cis*,*fac*-[Mo( $\eta^3$ -allyl)(CO)<sub>2</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (1) and *fac*-[Mn(CO)<sub>3</sub>(Hpz<sup>\*</sup>)<sub>3</sub>]BAr'<sub>4</sub> (Hpz<sup>\*</sup> = Hdmpz (4a) or H'Bupz (4b)) are labile toward most anions. The geometry of the adduct formed between the cationic complex and perrhenate (the only anion for which no pyrazole substitution at the manganese center takes place) is the same for manganese and rhenium complexes.

Although the hydrogen bonding between these tris-(pyrazole) compounds and anions occurs mainly through two of the three N-H groups, the presence of the third pyrazole ligand gives rise to a large enhancement of the binding strength compared with the bis(pyrazole) compound *fac,cis*-[Re(CO)<sub>3</sub>(CN'Bu)(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (11).

Taking into account the stability of the receptors, the strength of anion binding, and the difference in binding strength as a response to the nature of the anion, the rhenium receptors with 3,5-dimethylpyrazole or *tert*-butylpyrazole perform better than complexes of Mo or Mn and than Re complexes with nonsubstituted pyrazole, 3(5)-phenylpyrazole or indazole.

## **Experimental Section**

All manipulations were carried out under a nitrogen atmosphere using Schlenk techniques. Compounds 1,6 [MnCl(CO)<sub>5</sub>],<sup>13</sup> [MnBr-(CO)<sub>5</sub>],<sup>13</sup> and [ReBr(CO)<sub>5</sub>]<sup>14</sup> were prepared as previously reported. Tetrabutylammonium salts were purchased from Fluka or Aldrich. Deuterated acetonitrile and dichloromethane (Cambridge Isotope Laboratories, Inc.) were stored under nitrogen in Young tubes and used without further purification. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Advance 300, DPX-300, or Advance 400 spectrometer. NMR spectra are referred to the internal residual solvent peak for <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR. IR solution spectra were obtained in a Perkin-Elmer FT 1720-X spectrometer using 0.2 mm CaF<sub>2</sub> cells. NMR samples were prepared under nitrogen using Kontes manifolds purchased from Aldrich. Oven-dried 5 mm NMR tubes were subjected to several vacuum-nitrogen cycles, filled with the solution of the receptor (prepared separately in a Schlenk tube, typically in a  $10^{-2}$  M concentration in CD<sub>3</sub>CN) by means of a 1 mL syringe, and stoppered with rubber septa. After the NMR spectrum of the receptor was recorded, the successive aliquots of the tetrabutylammonium salt (typically  $4 \times 10^{-2}$  M in CD<sub>3</sub>CN, separately prepared and kept in a septum-stoppered vial during the titration) were injected through the septum using Hamilton microsyringes (10–100  $\mu$ L). The volume of each addition was 10  $\mu$ L before reaching the saturation zone (nearly horizontal line of the titration profile) and 20 or 40  $\mu$ L afterward. When the change in  $\delta$  is small (as for ReO<sub>4</sub><sup>-</sup>), 20  $\mu$ L of salt solution was added from the beginning. Data were treated using the WinEQNMR program.<sup>15</sup>

Synthesis of  $[MoCl(\eta^3-C_3H_5)(CO)_2(Hdmpz)_2]$  (2). A solution of [Mo(CO)<sub>6</sub>] (0.100 g, 0.379 mmol) in thf (20 mL) was refluxed until the IR spectrum showed the disappearance of the  $\nu$ (CO) band corresponding to the starting material (1981 cm<sup>-1</sup>, ca. 8 h). The resulting solution was then allowed to reach room temperature, allyl chloride (0.28 mL, 3.800 mmol) was added, and the mixture was refluxed and stirred for 15 min. The solvent was evaporated under reduced pressure to a volume of 2 mL, CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and Hdmpz (0.073 g, 0.380 mmol) were added, and the reaction mixture was stirred for 10 min. Then the resulting yellow solution was concentrated under vacuum to a volume of 5 mL; addition of hexane caused the precipitation of a yellow solid which was washed with hexane (2 × 20 mL). Yield: 0.135 g, 84%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  1939, 1838 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>): δ 11.41 [s, br, 1H, NH of Hdmpz], 10.71 [s, br, 1H, NH of Hdmpz], 6.00 [s, 1H, CH of Hdmpz], 5.83 [s, 1H, CH of Hdmpz], 3.98 [s, 1H,  $H_c$  of  $\eta^3$ -C<sub>3</sub>H<sub>5</sub>], 3.76 [m, 1H,  $H_{syn}$  of  $\eta^3$ -C<sub>3</sub>H<sub>5</sub>], 3.09 [m, 1H,  $H_{syn}$  of  $\eta^3$ -C<sub>3</sub>H<sub>5</sub>], 2.96 [s, 3H, CH<sub>3</sub> of Hdmpz], 2.26 [s, 3H, CH<sub>3</sub> of Hdmpz], 2.15 [s, 3H,  $CH_3$  of Hdmpz], 2.09 [s, 3H,  $CH_3$  of Hdmpz], 1.57 [d ( ${}^{3}J_{HH}$ = 11 Hz), 1H,  $H_{anti}$  of  $\eta^3$ -C<sub>3</sub>H<sub>5</sub>], 1.25 [d (<sup>3</sup>J<sub>HH</sub> = 11 Hz), 1H,  $H_{anti}$  of  $\eta^3$ -C<sub>3</sub>H<sub>5</sub>]. Anal. Calcd for C<sub>15</sub>H<sub>21</sub>ClMoN<sub>4</sub>O<sub>2</sub>: C, 42.82; H, 5.03; N, 13.32. Found: C, 42.74; H, 5.11; N, 13.29.

Synthesis of [Mn(CO)<sub>3</sub>(Hdmpz)<sub>3</sub>]BAr'<sub>4</sub> (4a). AgOTf (0.140 g, 0.546 mmol) was added to a solution of [MnBr(CO)<sub>5</sub>] (0.150 g, 0.546 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and the mixture was stirred in the dark for 15 min. The resulting AgBr was filtered off and the solvent evaporated under reduced pressure. The residue was redissolved in toluene (30 mL), Hdmpz (0.158 g, 1.638 mmol) was added, and the mixture was refluxed for 20 min. The yellow solution was evaporated to dryness. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), NaBAr'<sub>4</sub> (0.484 g, 0.546 mmol) was added, and the mixture was stirred at room temperature for 15 min. The solution was filtered via canula, and the solvent was reduced under vacuum to a volume of 5 mL. Addition of hexane (10 mL) caused the precipitation of a yellow solid, which was washed with hexane (2  $\times$  20 mL). Slow diffusion of hexane (15 mL) into a solution of 4a in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) afforded yellow crystals, one of which was employed for an X-ray structural determination. Yield: 0.599 g, 85%. IR (CH<sub>2</sub>Cl<sub>2</sub>): v 2043, 1949 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  8.82 [s, br, 3H, NH of Hdmpz], 7.70 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.54 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 6.24 [s, 3H, CH of Hdmpz], 2.43 [s, 9H,  $CH_3$  of Hdmpz], 2.19 [s, 9H,  $CH_3$  of Hdmpz]. <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  219.8 [CO], 162.2 [q (<sup>1</sup>J<sub>CB</sub> = 49.9 Hz), C<sup>i</sup> of BAr'<sub>4</sub>], 157.9, 145.9 [C<sup>3</sup> and C<sup>5</sup> of Hdmpz], 135.2 [C<sup>o</sup> of BAr'<sub>4</sub>], 129.3 [q  $({}^{2}J_{CF} = 33.1 \text{ Hz}), C^{m} \text{ of BAr}'_{4}], 125.0 \text{ [q } ({}^{1}J_{CF} = 271.7 \text{ Hz}), CF_{3}$ of BAr'<sub>4</sub>], 117.9 [C<sup>p</sup> of BAr'<sub>4</sub>], 110.6 [C<sup>4</sup> of Hdmpz], 15.2 [CH<sub>3</sub> of Hdmpz], 11.2 [CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>50</sub>H<sub>36</sub>BF<sub>24</sub>-MnN<sub>6</sub>O<sub>3</sub>: C, 46.53; H, 2.81; N, 6.51. Found: C, 46.68; H, 3.05; N. 6.48.

Synthesis of  $[Mn(CO)_3(H'Bupz)_3]BAr'_4$  (4b). Compound 4b was prepared as described above for 4a from  $[MnBr(CO)_5]$  (0.150 g, 0.546 mmol), AgOTf (0.140 g, 0.546 mmol), H'Bupz (0.203 g, 1.638 mmol), and NaBAr'\_4 (0.484 g, 0.546 mmol). Slow diffusion of hexane into a concentrated solution of 4b in CH<sub>2</sub>Cl<sub>2</sub> afforded

<sup>(13)</sup> Schmidt, S. P.; Trogler, W. C.; Basolo, F. Inorg. Synth. 1990, 28, 160.

<sup>(14)</sup> Reimer, K. J.; Shaver, A. Inorg. Synth. 1990, 28, 160.

<sup>(15)</sup> Hynes, M. J. J. Chem. Soc., Dalton Trans. 1993, 311.

crystals, one of which was employed for an X-ray determination. Yield: 0.608 g, 81%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2048, 1956 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  8.92 [s, br, 3H, NH of H'Bupz], 7.74 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.61 [s, br, 3H, CH of H'Bupz], 7.58 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 6.48 [s, br, 3H, CH of H'Bupz], 1.23 [s, 27H, CH<sub>3</sub> of H'Bupz]. <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  218.0 [CO], 162.1 [q (<sup>1</sup>J<sub>CB</sub> = 49.8 Hz), C<sup>i</sup> of BAr'<sub>4</sub>], 159.7, 146.6 [C<sup>3</sup> and C<sup>5</sup> of H'Bupz], 135.2 [C<sup>o</sup> of BAr'<sub>4</sub>], 129.3 [q (<sup>2</sup>J<sub>CF</sub> = 30.0 Hz), C<sup>m</sup> of BAr'<sub>4</sub>], 124.9 [q (<sup>1</sup>J<sub>CF</sub> = 272.6 Hz), CF<sub>3</sub> of BAr'<sub>4</sub>], 117.8 [C<sup>p</sup> of BAr'<sub>4</sub>], 106.5 [C<sup>4</sup> of H'Bupz], 31.8 [C(CH<sub>3</sub>)<sub>3</sub> of H'Bupz], 29.7 [CH<sub>3</sub> of H'Bupz]. Anal. Calcd for C<sub>56</sub>H<sub>48</sub>BF<sub>24</sub>MnN<sub>6</sub>O<sub>3</sub>: C, 48.93; H, 3.52; N, 6.12. Found: C, 49.25; H, 3.35; N, 5.90.

**Synthesis of [MnCl(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>] (5a).** To a solution of [MnCl(CO)<sub>5</sub>] (0.060 g, 0.260 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added Hdmpz (0.050 g, 0.520 mmol), and the reaction mixture was refluxed for 2 h. The resulting yellow solution was concentrated under vacuum to a volume of 5 mL; addition of hexane caused the precipitation of a yellow solid which was washed with hexane (2  $\times$  20 mL). Yield: 0.089 g, 93%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2033, 1940, 1911 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  10.74 [s, br, 2H, NH of Hdmpz], 5.94 [s, br, 2H, CH of Hdmpz], 2.25 [s, br, 6H, 2  $\times$  CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>13</sub>H<sub>16</sub>ClMnN<sub>4</sub>O<sub>3</sub>: C, 42.85; H, 4.40; N, 15.28. Found: C, 43.12; H, 4.54; N, 15.98.

**Synthesis of [MnCl(CO)<sub>3</sub>(H'Bupz)<sub>2</sub>] (5b).** Compound **5b** was prepared as described above for **5a** from [MnCl(CO)<sub>5</sub>] (0.060 g, 0.260 mmol) and H'Bupz (0.065 g, 0. 520 mmol). Compound **5b** was obtained as a yellow powder. Yield: 0.099 g, 90%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2136, 1944, 1914 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  11.62 [s, br, 2H, NH of H'Bupz], 7.60 [s, br, 2H, CH of H'Bupz], 6.14 [s, br, 2H, CH of H'Bupz], 1.28 [s, br, 18H, (CH<sub>3</sub>)<sub>3</sub> of H'Bupz]. Anal. Calcd for C<sub>17</sub>H<sub>24</sub>ClMnN<sub>4</sub>O<sub>3</sub>: C, 48.29; H, 5.72; N, 13.25. Found: C, 47.98; H, 5.89; N, 12.88.

**Synthesis of [Mn(ONO<sub>2</sub>)(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>] (6).** A mixture of [MnBr(CO)<sub>5</sub>] (0.100 g, 0.364 mmol) and Hdmpz (0.070 g, 0.728 mmol) was refluxed in toluene (20 mL) for 30 min. The solution was evaporated to dryness, the yellow residue redissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), AgNO<sub>3</sub> (0.062 g, 0.364 mmol) added, and the reaction mixture stirred for 45 min. The resulting solution was filtered off the white solid (AgBr) via canula and concentrated under reduced pressure to a volume of 5 mL. Slow diffusion of hexane (15 mL) at -20 °C afforded yellow crystals, one of which was employed for an X-ray analysis. Yield: 0.102 g, 71%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2040, 1947, 1923 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  10.49 [s, br, 2H, NH of Hdmpz], 5.96 [s, 2H, CH of Hdmpz], 2.21 [s, 6H, CH<sub>3</sub> of Hdmpz], 2.19 [s, 6H, CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>13</sub>H<sub>16</sub>-MnN<sub>5</sub>O<sub>6</sub>: C, 39.71; H, 4.10; N, 17.81. Found: C, 39.68; H, 4.04; N, 17.87.

Synthesis of [Re(CO)<sub>5</sub>(Hdmpz)]OTf (9). To a solution of [Re(OTf)(CO)<sub>5</sub>] (0.050 g, 0.113 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added Hdmpz (0.011 g, 0.113 mmol), and the mixture was stirred at room temperature for 30 min. The resulting colorless solution was concentrated under reduced pressure to a volume of 5 mL. Slow diffusion of hexane (15 mL) at -20 °C afforded colorless crystals, one of which was employed for an X-ray analysis. Yield: 0.059 g, 94%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2162, 2053, 2031 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  13.10 [s, br, 1H, NH of Hdmpz], 7.26 [s, 1H, CH of Hdmpz], 2.40 [s, 3H, CH<sub>3</sub> of Hdmpz], 2.34 [s, 3H, CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>11</sub>H<sub>8</sub>F<sub>3</sub>N<sub>2</sub>O<sub>8</sub>ReS: C, 21.47; H, 1.44; N, 5.01. Found: C, 21.39; H, 1.51; N, 4.98.

Synthesis of  $[\text{Re}(\text{CO})_4(\text{Hdmpz})_2]\text{BAr'}_4$  (10). To a solution of compound  $[\text{Re}(\text{CO})_5(\text{Hdmpz})]\text{OTf}$  (9) (0.063 g, 0.113 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 mL) was added NaBAr'\_4 (0.100 g, 0.113 mmol), and the reaction mixture was stirred at room temperature for 15 min.

The colorless solution was filtered and evaporated to dryness under reduced pressure. The residue was extracted with toluene and Hdmpz (0.011 g, 0.113 mmol) was added and refluxed for 30 min affording a mixture of a tetracarbonylic and a tricarbonylic species. The solvent was evaporated in vacuum and the white residue redissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL); slow diffusion of hexane (20 mL) at -20 °C afforded colorless crystals of the tetracarbonylic compound **10**, one of which was employed for an X-ray analysis. Yield: 0.040 g, 26%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2017, 2014, 2011, 1972 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  9.35 [s, br, 2H, NH of Hdmpz], 7.74 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.61 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 6.20 [s, 2H, CH of Hdmpz], 2.34 [s, 6H, CH<sub>3</sub> of Hdmpz], 2.21 [s, 6H, CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>46</sub>H<sub>28</sub>BF<sub>24</sub>N<sub>4</sub>O<sub>4</sub>Re: C, 40.81; H, 2.08; N, 4.14. Found: C, 40.78; H, 2.12; N, 4.19.

Synthesis of [Re(CN'Bu)(CO)<sub>3</sub>(Hdmpz)<sub>2</sub>]BAr'<sub>4</sub> (11). A mixture of [ReBr(CO)<sub>5</sub>] (0.100 g, 0.246 mmol) and Hdmpz (0.047 g, 0.492 mmol) in toluene (20 mL) was refluxed for 30 min affording a colorless solution that was evaporated to dryness under reduced pressure. The residue was redissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), AgOTf (0.063 g, 0.246 mmol) was added, and the reaction mixture was allowed to stir at room temperature for 1 h. The solution was then filtered via canula, and CN'Bu (0.027 mL, 0.246 mmol) was added. After 15 min of stirring at room temperature, the solution was concentrated to a volume of 10 mL and addition of hexane (20 mL) caused the precipitation of **11** as a white microcrystalline solid, which was washed with hexane  $(2 \times 15 \text{ mL})$ . Slow diffusion of hexane (20 mL) into a concentrated solution of compound 11 in CH<sub>2</sub>Cl<sub>2</sub> at -20 °C afforded colorless crystals, one of which was employed for an X-ray analysis. Yield: 0.250 g, 72%. IR (CH<sub>2</sub>Cl<sub>2</sub>): v 2186 (CN); v 2038, 1960, 1940 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR  $(CD_2Cl_2)$ :  $\delta$  9.20 [s, br, 2H, NH of Hdmpz], 7.73 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.58 [m, 4H, H<sub>p</sub> of BAr'4], 6.07 [s, 2H, CH of Hdmpz], 2.26 [s, 6H, CH<sub>3</sub> of Hdmpz], 2.16 [s, 6H, CH<sub>3</sub> of Hdmpz], 1.53 [s, 9H, CN<sup>t</sup>Bu]. <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  191.6 [CO], 191.5 [2 × CO], 164.1 [q ( ${}^{1}J_{CB} = 49.7$  Hz),  $C^{i}$  of BAr'<sub>4</sub>], 158.1, 147.3, [ $C^{3}$ and  $C^5$  of Hdmpz], 137.2 [ $C^{\circ}$  of BAr'<sub>4</sub>], 131.2 [q ( ${}^{2}J_{CF}$ = 31.3 Hz),  $C^{\rm m}$  of BAr'<sub>4</sub>], 127.0 [q ( ${}^{1}J_{\rm CF} = 272.3$  Hz),  $CF_3$  of BAr'<sub>4</sub>], 119.9 [C<sup>p</sup> of BAr'<sub>4</sub>], 110.2 [C<sup>4</sup> of Hdmpz], 62.2 [C(CH<sub>3</sub>)<sub>3</sub> of CN'Bu], 32.2 [CH<sub>3</sub> of CN<sup>*t*</sup>Bu], 17.1 [CH<sub>3</sub> of Hdmpz], 13.0 [CH<sub>3</sub> of Hdmpz]. Anal. Calcd for C<sub>50</sub>H<sub>37</sub>BF<sub>24</sub>N<sub>5</sub>O<sub>3</sub>Re: C, 46.63; H, 2.65; N, 4.97. Found: C, 46.81; H, 2.48; N, 5.21.

Synthesis of [Mn(CO)<sub>3</sub>(Hpz)<sub>3</sub>]BAr'<sub>4</sub> (12). Hpz (0.059 g, 0.872 mmol) was added to a solution of [Mn(OTf)(CO)<sub>5</sub>] (0.100 g, 0.291 mmol) in toluene (20 mL), and the mixture was refluxed for 1 h. The solvent was then evaporated to dryness under reduced pressure, the residue was redissolved in  $CH_2Cl_2$  (20 mL), NaBAr'<sub>4</sub> (0.256 g, 0.291 mmol) was added, and the reaction mixture was allowed to stir at room temperature for 15 min. The solution was filtered off (via canula) the white solid (NaOTf) and concentrated to a volume of 5 mL; addition of hexane (20 mL) caused the precipitation of 12 as a yellow solid, which was washed with hexane  $(2 \times 15 \text{ mL})$ . Yield: 0.281 g, 80%. IR (CH<sub>2</sub>Cl<sub>2</sub>): v 2049, 1958 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  9.88 [s, br, 3H, NH of Hpz], 7.86 [d (<sup>3</sup>J<sub>HH</sub> = 1.7 Hz), 3H, CH of Hpz], 7.72 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.60 [s, br, 3H, CH of Hpz], 7.57 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 6.67 [m, 3H, CH of Hpz]. Anal. Calcd for C<sub>44</sub>H<sub>24</sub>BF<sub>24</sub>MnN<sub>6</sub>O<sub>3</sub>: C, 43.80; H, 2.00; N, 6.97. Found: C, 43.62; H, 2.17; N, 7.08.

**Synthesis of [Re(CO)<sub>3</sub>(Hpz)<sub>3</sub>]BAr'<sub>4</sub> (13).** Compound **13** was prepared as described above for **12** from [Re(OTf)(CO)<sub>5</sub>] (0.100 g, 0.210 mmol), Hpz (0.043 g, 0.632 mmol), and NaBAr'<sub>4</sub> (0.186 g, 0.210 mmol). Compound **13** was obtained as a yellow powder. Yield: 0.228 g, 81%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2042, 1936 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  10.26 [s, br, 3H, NH of Hpz], 7.85 [m, 3H, CH

Table 2. Selected Crystal, Measurement, and Refinement Data for Compounds 3, 4a,b, 6, 7a,b, 8-11, 16, and 17

param	3	<b>4</b> a	4b	6	7a	7b
formula	C15H21M0N4O6Re	C50H36BF24MnN6O3	C56H48BF24MnN6O3	C18H24MnN7O6	C36H48Mn2N12O14Re	C72H84BF24MnN7O7Re
fw	635.50	1290.60	1374.75	489.38	1655.14	1867.41
cryst syst	triclinic	monoclinic	triclinic	monoclinic	monoclinic	monoclinic
snace group	PI	$P2_{1/n}$	PI	$P2_1/c$	$P2_1/c$	$P2_1/c$
a Å	9 907(10)	14775(3)	10.814(7)	11.865(3)	13 887(6)	18 566(3)
h Å	14 555(14)	26.002(6)	15,800(7)	14.837(4)	15.524(6)	28 554(5)
o, Å	14.333(14) 16.175(16)	20.092(0) 15.480(3)	10.850(0)	14.037(4) 14.004(4)	13.324(0)	18475(2)
C, A	10.173(10) 70.44(2)	13.469(3)	19.030(9)	14.004(4)	25.011(10)	18.473(3)
a, deg	79.44(2)	90	74.820(14)	90	90	90
p, deg	/5./18(16)	105.468(4)	/6.3/4(15)	110.941(5)	102.224(8)	119.043(3)
$\gamma$ , deg	72.794(19)	90	83.188(146)	90	90	90
V, A <sup>3</sup>	2144(4)	5755(2)	3175(3)	2302.6(11)	4975(4)	8563(3)
Z	4	4	2	4	4	4
F(000)	1216	2592	1392	1016	2640	3768
$D_{\text{calcd}}$ , g cm <sup>-3</sup>	1.969	1.490	1.438	1.412	1.809	1.449
radiatn ( $\lambda$ , A)	Μο Κα, 0.710 73	Μο Κα, 0.710 73	Μο Κα, 0.710 73	Μο Κα, 0.710 73	Μο Κα, 0.710 73	Μο Κα, 0.710 73
$\mu$ , mm <sup>-1</sup>	6.262	0.353	0.324	0.621	5.417	1.663
cryst size, mm	$0.11 \times 0.15 \times 0.18$	$0.22 \times 0.23 \times 0.39$	$0.18 \times 0.35 \times 0.48$	$0.26 \times 0.22 \times 0.11$	$0.22 \times 0.25 \times 0.45$	$0.08 \times 0.20 \times 0.31$
temp, K	296(2)	293(2)	296(2)	293(2)	293(2)	296(2)
$\theta$ limits, deg	1.31-23.41	1.56-23.30	1.09-23.68	1.84-23.37	1.50-23.35	1.25-23.31
min/max h, k, l	-10/10, -14/16,	-16/16, -29/27,	-11/12, -17/17,	-2/13, -11/16,	-14/15, -17/17,	-20/19, -22/31,
	-14/17	-17/15	-22/22	-15/15	-22/26	-20/19
collcd reflcns	9413	25 734	14 582	10 229	21 836	38 286
unique reflcns	5976	8295	9319	3334	7155	12 336
abs	SADABS	SADABS	SADABS	SADABS	SADABS	SADABS
params/restraints	495/0	783/0	842/0	307/0	625/0	1039/0
GOF on $F^2$	1.056	1.043	1.061	1.001	1.027	1.011
$R_1$ (on $F, I > 2\sigma(I)$ )	0.0925	0.0870	0.0771	0.0405	0.0562	0.0890
wR <sub>2</sub> (on $F^2$ , all data)	0.2672	0.2888	0.2442	0.1118	0.1436	0.2639
max/min $\Delta \rho$ , e Å <sup>-3</sup>	3.874 and -5.102	0.859 and -0.450	1.073 and -0.599	0.529 and -0.300	5.434 and -1.917	1.828 and -0.709
param	8	9	10	11	16	17
param formula	<b>8</b> C <sub>36</sub> H <sub>48</sub> N <sub>12</sub> O <sub>14</sub> Re <sub>4</sub>	<b>9</b> C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS	<b>10</b> C <sub>46</sub> H <sub>28</sub> BF <sub>24</sub> N <sub>4</sub> O <sub>4</sub> Re	11 C <sub>50</sub> H <sub>37</sub> BF <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Re	16 C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub>	17 C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re
param formula fw	<b>8</b> C <sub>36</sub> H <sub>48</sub> N <sub>12</sub> O <sub>14</sub> Re <sub>4</sub> 1617.66	<b>9</b> C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45	<b>10</b> C <sub>46</sub> H <sub>28</sub> BF <sub>24</sub> N <sub>4</sub> O <sub>4</sub> Re 1353.73	11 C <sub>50</sub> H <sub>37</sub> BF <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Re 1408.86	<b>16</b> C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16	<b>17</b> C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re 724.09
param formula fw cryst syst	<b>8</b> C <sub>36</sub> H <sub>48</sub> N <sub>12</sub> O <sub>14</sub> Re <sub>4</sub> 1617.66 monoclinic	<b>9</b> C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic	<b>10</b> C <sub>46</sub> H <sub>28</sub> BF <sub>24</sub> N <sub>4</sub> O <sub>4</sub> Re 1353.73 triclinic	<b>11</b> C <sub>50</sub> H <sub>37</sub> BF <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Re 1408.86 monoclinic	<b>16</b> C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16 monoclinic	17 C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re 724.09 orthorhombic
param formula fw cryst syst space group	<b>8</b> C <sub>36</sub> H <sub>48</sub> N <sub>12</sub> O <sub>14</sub> Re <sub>4</sub> 1617.66 monoclinic <i>P</i> 2 <sub>1</sub> / <i>c</i>	<b>9</b> C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n	<b>10</b> C <sub>46</sub> H <sub>28</sub> BF <sub>24</sub> N <sub>4</sub> O <sub>4</sub> Re 1353.73 triclinic <i>P</i> 1	<b>11</b> C <sub>50</sub> H <sub>37</sub> BF <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Re 1408.86 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i>	<b>16</b> C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i>	<b>17</b> C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re 724.09 orthorhombic <i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>
param formula fw cryst syst space group a, Å	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic $P_{21/c}$ 13.926(3)	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5)	10 $C_{46}H_{28}BF_{24}N_4O_4Re$ 1353.73 triclinic $P\bar{1}$ 10.6683(17)	11 C <sub>50</sub> H <sub>37</sub> BF <sub>24</sub> N <sub>5</sub> O <sub>3</sub> Re 1408.86 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i> 14.532(4)	<b>16</b> C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i> 11.790(7)	17 C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re 724.09 orthorhombic P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub> 10.7796(8)
$\begin{array}{c} \hline param \\ \hline formula \\ fw \\ cryst syst \\ space group \\ a, \mathring{A} \\ b, \mathring{A} \end{array}$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic $P_{21/c}$ 13.926(3) 15.559(3)	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i> 9.407(5) 18.291(10)	$\frac{10}{C_{46}H_{28}BF_{24}N_4O_4Re}$ 1353.73 triclinic $P\bar{1}$ 10.6683(17) 12.405(2)	$\frac{11}{C_{50}H_{37}BF_{24}N_5O_3Re}$ 1408.86 monoclinic $P2_1/n$ 14.532(4) 23.467(6)	<b>16</b> C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16 monoclinic <i>P</i> 2 <sub>1</sub> / <i>n</i> 11.790(7) 20.368(12)	<b>17</b> C <sub>24</sub> H <sub>18</sub> ClN <sub>6</sub> O <sub>7</sub> Re 724.09 orthorhombic <i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub> 10.7796(8) 12.6297(10)
param formula fw cryst syst space group $a, \mathring{A}$ $b, \mathring{A}$ $c, \mathring{A}$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic $P_{2_1/c}$ 13.926(3) 15.559(3) 23.677(5)	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5) 18.291(10) 10.210(6)	$\begin{array}{c} 10\\ \hline C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3) \end{array}$	$\frac{11}{C_{50}H_{37}BF_{24}N_5O_3Re}$ 1408.86 monoclinic $P_{2_1/n}$ 14.532(4) 23.467(6) 17.381(4)	16 C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O <sub>10</sub> Re <sub>2</sub> 1091.16 monoclinic P2 <sub>1</sub> /n 11.790(7) 20.368(12) 17.485(10)	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}ClN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_{12}l_{21} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \end{array}$
param formula fw cryst syst space group a, Å b, Å c, Å a, deg	8 C <sub>36</sub> H <sub>48</sub> N <sub>12</sub> O <sub>14</sub> Re <sub>4</sub> 1617.66 monoclinic <i>P</i> 2 <sub>1</sub> / <i>c</i> 13.926(3) 15.559(3) 23.677(5) 90	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5) 18.291(10) 10.210(6) 90	$\begin{array}{c} \textbf{10} \\ \hline C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P_{21/n}\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90 \end{array}$	$\begin{array}{c} \textbf{16} \\ \hline C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}ClN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_12_12_1 \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \end{array}$
param formula fw cryst syst space group a,  Å b,  Å c,  Å $\alpha, \text{ deg}$ $\beta, \text{ deg}$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic $P_{2_1/c}$ 13.926(3) 15.559(3) 23.677(5) 90 102.265(4)	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11)	$\begin{array}{c} \textbf{10} \\ \hline C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P_{21/n}\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5) \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P_{21}/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}ClN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_12_12_1 \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ \end{array}$
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90	$\begin{array}{c} 10\\ C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90 \end{array}$	$\begin{array}{c} \textbf{16} \\ \hline C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P_{21/n} \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}CIN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_12_12_1 \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 90 \\ \end{array}$
param       formula       fw       cryst syst       space group $a$ , Å $b$ , Å $c$ , Å $\alpha$ , deg $\beta$ , deg $\gamma$ , deg $\gamma$ , Å	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic <i>P</i> 2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19)	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754 9(17)	$\begin{array}{c} 10 \\ \hline C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P_{21}/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}CIN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_12_12_1 \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 90 \\ 90 \\ 2673.8(4) \end{array}$
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, deg$ $\gamma, A^3$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_{4}\\ 1617.66\\ monoclinic\\ P2_{1/c}\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\end{array}$	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4	$\begin{array}{c} 10\\ C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ 2578.0(7)\\ 2\end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\end{array}$	$\begin{array}{c} \textbf{16} \\ \hline C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ 4192(4) \\ 4 \end{array}$	$\begin{array}{c} 17\\ \hline C_{24}H_{18}CIN_6O_7Re\\ 724.09\\ orthorhombic\\ P2_{12}_{12}_{1}\\ 10.7796(8)\\ 12.6297(10)\\ 19.6399(15)\\ 90\\ 90\\ 90\\ 2673.8(4)\\ 4\end{array}$
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, A^3$ $Z$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_{4}\\ 1617.66\\ monoclinic\\ P2_{1/c}\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ \end{array}$	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080	$\begin{array}{c} 10\\ C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ 2578.0(7)\\ 2\\ 1320\end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\end{array}$	$\begin{array}{c} \textbf{16} \\ \hline C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ 4192(4) \\ 4 \\ 2120 \\ \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}CIN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_{12}_{12}_{1} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 90 \\ 90 \\ 2673.8(4) \\ 4 \\ 1408 \end{array}$
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \delta^3$ $Z$ $F(000)$ $D_{able} q cm^{-3}$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_4\\ 1617.66\\ monoclinic\\ P2_1/c\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2, 143\\ \end{array}$	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ \end{array}$	$\begin{array}{c} \textbf{16} \\ \hline C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ 4192(4) \\ 4 \\ 2120 \\ 1,729 \\ \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}ClN_6O_7Re \\ 724.09 \\ orthorhombic \\ P2_{12}l_{21} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 2673.8(4) \\ 4 \\ 1408 \\ 1799 \\ \end{array}$
param       formula       fw       cryst syst       space group $a, \hat{A}$ $b, \hat{A}$ $c, \hat{A}$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \hat{A}^3$ $Z$ $F(000)$ $D_{calcd}$ g cm <sup>-3</sup> $radiatn (\lambda^{-1})$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_{4}\\ 1617.66\\ monoclinic\\ P2_{1}/c\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2.143\\ Mo \ Kg, 0.710, 73\\ \end{array}$	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Kg 0.710.73	$\begin{array}{c} 10\\ C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ 2578.0(7)\\ 2\\ 1320\\ 1.744\\ Mo \ Kg\ 0\ 710\ 73\\ \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo \ Kg\ 0\ 710\ 73\\ \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P2_1/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)           4           2120           1.729           Mo K at 0.710.73	17 $C_{24}H_{18}CIN_6O_7Re$ 724.09 orthorhombic $P2_{12}_{12}_{1}$ 10.7796(8) 12.6297(10) 19.6399(15) 90 90 90 2673.8(4) 4 1408 1.799 Mo Kg. 0.710.73
param formula fw cryst syst space group a, Å b, Å c, Å a, deg $\beta, deg$ $\gamma, de$	8 $C_{36}H_{48}N_{12}O_{14}Re_4$ 1617.66 monoclinic $P_{21/c}$ 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697	9 C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>2</sub> O <sub>8</sub> ReS 571.45 monoclinic P2 <sub>1</sub> /n 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Kα, 0.710 73 7.116	$\begin{array}{c} 10\\ \hline C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ 2578.0(7)\\ 2\\ 1320\\ 1.744\\ Mo\ K\alpha, 0.710\ 73\\ 2.490\end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P2_1/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)           4           2120           1.729           Mo Kα, 0.710 73           5 829	17 $C_{24}H_{18}CIN_6O_7Re$ 724.09           orthorhombic $P2_{12}_{12_1}$ 10.7796(8)           12.6297(10)           19.6399(15)           90
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $a, deg$ $\beta, deg$ $\gamma, deg$ $\alpha, deg$ $\alpha, deg$ $\gamma, $	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_4\\ 1617.66\\ monoclinic\\ P2_{1/c}\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2.143\\ Mo\ K\alpha, 0.710\ 73\\ 9.697\\ 0.13 \times 0.22 \times 0.49 \end{array}$	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Ka, 0.710 73 7.116 0.245 $\times$ 0.12	$\begin{array}{c} 10\\ \hline C_{46}H_{28}BF_{24}N_4O_4Re\\ 1353.73\\ triclinic\\ P\bar{1}\\ 10.6683(17)\\ 12.405(2)\\ 19.975(3)\\ 95.593(4)\\ 95.593(4)\\ 95.245(3)\\ 99.650(3)\\ 2578.0(7)\\ 2\\ 1320\\ 1.744\\ Mo\ K\alpha, 0.710\ 73\\ 2.490\\ 0.27 \times 0.16 \times 0.11\\ \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P_{21/n}\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\\ 0\ 42 \\ \sim 0.31 \\ \times 0.20\\ \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P2_1/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)           4           2120           1.729           Mo Ka, 0.710 73           5.829           0.30 $\geq 0.14 \geq 0.12$	17 $C_{24}H_{18}CIN_6O_7Re$ 724.09           orthorhombic $P2_{12}I_{21}$ 10.7796(8)           12.6297(10)           19.6399(15)           90
param formula fw cryst syst space group a, Å b, Å c, Å $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, deg$ $\gamma, deg$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_{4}\\ 1617.66\\ monoclinic\\ P2_{1}/c\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2.143\\ Mo\ K\alpha, 0.710\ 73\\ 9.697\\ 0.13\times 0.22\times 0.49\\ 202(2)\\ \end{array}$	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{2_1/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Ka, 0.710 73 7.116 0.34 × 0.15 × 0.12 206(2)	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 202(2) \end{array}$	$\begin{array}{c} 11 \\ C_{50}H_{37}BF_{24}N_5O_3Re \\ 1408.86 \\ monoclinic \\ P_{21/n} \\ 14.532(4) \\ 23.467(6) \\ 17.381(4) \\ 90 \\ 103.523(5) \\ 90 \\ 5763(2) \\ 4 \\ 2768 \\ 1.624 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.231 \\ 0.42 \times 0.31 \times 0.20 \\ 206(2) \end{array}$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param       formula       fw       cryst syst       space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, Å$ $z$ $F(000)$ $D_{calcd}, g \operatorname{cm}^{-3}$ radiatn $(\lambda, Å)$ $\mu, \operatorname{mm}^{-1}$ cryst size, mm       temp, K $d \lim time ta deg$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 150–23.28	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.22–23.28	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{array}{c} 11 \\ C_{50}H_{37}BF_{24}N_5O_3Re \\ 1408.86 \\ monoclinic \\ P2_1/n \\ 14.532(4) \\ 23.467(6) \\ 17.381(4) \\ 90 \\ 103.523(5) \\ 90 \\ 5763(2) \\ 4 \\ 2768 \\ 1.624 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.231 \\ 0.42 \times 0.31 \times 0.20 \\ 296(2) \\ 1.48 - 23.26 \end{array}$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\mu, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg $\min \langle m, \psi, h, h \rangle$	8 $C_{36}H_{48}N_{12}O_{14}Re_4$ 1617.66           monoclinic $P2_1/c$ 13.926(3)           15.559(3)           23.677(5)           90           102.265(4)           90           5013.2(19)           4           3040           2.143           Mo Kα, 0.710 73           9.697           0.13 × 0.22 × 0.49           293(2)           1.50-23.28           -12/15	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21}/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -20(10)	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo Kα, 0.710 73\\ 2.231\\ 0.42\times0.31\times0.20\\ 296(2)\\ 1.48-23.26\\ -16/14\times-26/26 \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P2_1/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)           4           2120           1.729           Mo Kα, 0.710 73           5.829           0.30 × 0.14 × 0.12           296(2)           1.54-23.35           -13(12 - 22)(1)	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, deg$ $\gamma, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg $mi/max h, k, l$	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_4\\ 1617.66\\ monoclinic\\ P2_1/c\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2.143\\ Mo\ K\alpha, 0.710\ 73\\ 9.697\\ 0.13\times 0.22\times 0.49\\ 293(2)\\ 1.50-23.28\\ -12/15, -14/17,\\ -26/26\\ \end{array}$	$\begin{array}{c} 9\\ \hline \\ C_{11}H_8F_3N_2O_8ReS\\ 571.45\\ monoclinic\\ P2_1/n\\ 9.407(5)\\ 18.291(10)\\ 10.210(6)\\ 90\\ 92.686(11)\\ 90\\ 1754.9(17)\\ 4\\ 1080\\ 2.163\\ Mo\ K\alpha, 0.710\ 73\\ 7.116\\ 0.34\times 0.15\times 0.12\\ 296(2)\\ 2.23-23.28\\ -8/10, -20/19,\\ -11/10\\ \end{array}$	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P_{21/n}\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\\ 0.42\times 0.31\times 0.20\\ 296(2)\\ 1.48-23.26\\ -16/14, -26/26,\\ -17/19\\ \end{array}$	$\begin{array}{c} 16 \\ C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ 4192(4) \\ 4 \\ 2120 \\ 1.729 \\ Mo \ K\alpha, 0.710 \ 73 \\ 5.829 \\ 0.30 \times 0.14 \times 0.12 \\ 296(2) \\ 1.54-23.35 \\ -13/12, -22/21, \\ -18/19 \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}{\rm CIN}_6{\rm O}_7{\rm Re} \\ 724.09 \\ {\rm orthorhombic} \\ P_{21}_{21}_{21} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 2673.8(4) \\ 4 \\ 1408 \\ 1.799 \\ {\rm Mo}\ {\rm K}\alpha, 0.710\ 73 \\ 4.699 \\ 0.26 \times 0.17 \times 0.17 \\ 100(2) \\ 1.92 - 27.54 \\ -13/13, -16/16, -24/25 \\ \end{array}$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \delta = \beta$ $\beta, \deg$ $\gamma, \delta = \beta$ $\beta, \deg$ $\gamma, \delta = \beta$ $\gamma, \Theta = 0$ $\gamma, \delta = \beta$ $\gamma, \delta = \beta$ $\gamma, \deg$ $\gamma, \delta = \beta$ $\rho, \deg$ $\mu, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg         min/max $h, k, l$ collcd reflens	$\begin{array}{c} 8\\ \hline C_{36}H_{48}N_{12}O_{14}Re_4\\ 1617.66\\ monoclinic\\ P2_1/c\\ 13.926(3)\\ 15.559(3)\\ 23.677(5)\\ 90\\ 102.265(4)\\ 90\\ 5013.2(19)\\ 4\\ 3040\\ 2.143\\ Mo\ K\alpha, 0.710\ 73\\ 9.697\\ 0.13\times 0.22\times 0.49\\ 293(2)\\ 1.50-23.28\\ -12/15, -14/17,\\ -26/26\\ 21\ 799\\ \end{array}$	$\begin{array}{c} 9\\ \hline \\ C_{11}H_8F_3N_2O_8ReS\\ 571.45\\ monoclinic\\ P2_1/n\\ 9.407(5)\\ 18.291(10)\\ 10.210(6)\\ 90\\ 92.686(11)\\ 90\\ 1754.9(17)\\ 4\\ 1080\\ 2.163\\ Mo\ K\alpha, 0.710\ 73\\ 7.116\\ 0.34\times 0.15\times 0.12\\ 296(2)\\ 2.23-23.28\\ -8/10, -20/19,\\ -11/10\\ 7596 \end{array}$	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \\ 11 \ 378 \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\\ 0.42\times 0.31\times 0.20\\ 296(2)\\ 1.48-23.26\\ -16/14, -26/26,\\ -17/19\\ 15\ 378\\ \end{array}$	$\begin{array}{c} 16 \\ C_{36}H_{42}N_6O_{10}Re_2 \\ 1091.16 \\ monoclinic \\ P2_1/n \\ 11.790(7) \\ 20.368(12) \\ 17.485(10) \\ 90 \\ 93.392(12) \\ 90 \\ 4192(4) \\ 4 \\ 2120 \\ 1.729 \\ Mo \ K\alpha, 0.710 \ 73 \\ 5.829 \\ 0.30 \times 0.14 \times 0.12 \\ 296(2) \\ 1.54-23.35 \\ -13/12, -22/21, \\ -18/19 \\ 18 \ 667 \end{array}$	$\begin{array}{c} 17 \\ \hline C_{24}H_{18}{\rm CIN}_6{\rm O}_7{\rm Re} \\ 724.09 \\ orthorhombic \\ P2_{12}_{12}_{1} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 90 \\ 2673.8(4) \\ 4 \\ 1408 \\ 1.799 \\ {\rm Mo}\ {\rm K}\alpha, 0.710\ 73 \\ 4.699 \\ 0.26 \times 0.17 \times 0.17 \\ 100(2) \\ 1.92-27.54 \\ -13/13, -16/16, -24/25 \\ 22\ 887 \end{array}$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $rotooldbaa$ $\gamma, \deg$ $\mu, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg         min/max $h, k, l$ collcd reflens         unique reflexs	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50–23.28 -12/15, -14/17, -26/26 21 799 7195	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21}/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \\ 11 \ 378 \\ 7263 \end{array}$	$\begin{array}{c} 11 \\ C_{50}H_{37}BF_{24}N_5O_3Re \\ 1408.86 \\ monoclinic \\ P2_1/n \\ 14.532(4) \\ 23.467(6) \\ 17.381(4) \\ 90 \\ 103.523(5) \\ 90 \\ 103.523(5) \\ 90 \\ 5763(2) \\ 4 \\ 2768 \\ 1.624 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.231 \\ 0.42 \times 0.31 \times 0.20 \\ 296(2) \\ 1.48-23.26 \\ -16/14, -26/26, \\ -17/19 \\ 15 \ 378 \\ 8273 \end{array}$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, deg$ $\beta, deg$ $\gamma, mm^{-1}$ cryst size, mm         temp, K $\theta$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Ka, 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518 SADABS	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \\ 11 \ 378 \\ 7263 \\ SADABS \end{array}$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \varphi$ $\gamma, \varphi$ $\gamma, \varphi$ $\gamma, \varphi$ $\gamma, \varphi$ $\gamma, \varphi$ $\varphi$ $\varphi$ $\varphi$ <td><math display="block">\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}</math> 1617.66 monoclinic P2<sub>1</sub>/c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0</td> <td>9 <math>C_{11}H_8F_3N_2O_8ReS</math> 571.45 monoclinic <math>P_{21/n}</math> 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Ka, 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0</td> <td><math display="block">\begin{tabular}{lllllllllllllllllllllllllllllllllll</math></td> <td><math display="block">\begin{tabular}{ll} \hline \$L\$ 11\$ \$C_{50}H_{37}BF_{24}N_5O_3Re\$ \$1408.86\$ \$monoclinic\$ \$P_{21}/n\$ \$14.532(4)\$ \$23.467(6)\$ \$17.381(4)\$ \$90\$ \$103.523(5)\$ \$90\$ \$5763(2)\$ \$4\$ \$2768\$ \$1.624\$ \$Mo Kα, 0.710 73\$ \$2.231\$ \$0.42 \$\$\$\$\$\$\$\$\$0.42 \$</math></td> <td><math display="block">\begin{tabular}{lllllllllllllllllllllllllllllllllll</math></td> <td><math display="block">\begin{tabular}{lllllllllllllllllllllllllllllllllll</math></td>	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Ka, 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{ll} \hline $L$ 11$ $C_{50}H_{37}BF_{24}N_5O_3Re$ $1408.86$ $monoclinic$ $P_{21}/n$ $14.532(4)$ $23.467(6)$ $17.381(4)$ $90$ $103.523(5)$ $90$ $5763(2)$ $4$ $2768$ $1.624$ $Mo Kα, 0.710 73$ $2.231$ $0.42 $$$$$$$$$0.42 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, \hat{A}$ $b, \hat{A}$ $c, \hat{A}$ $\alpha, \deg$ $\beta, \deg$ $\gamma, qg$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0 1.044	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo Kα, 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23–23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0 1.053	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo \ K\alpha, 0.710 \ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \\ 11 \ 378 \\ 7263 \\ SADABS \\ 731/0 \\ 1.030 \\ \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\\ 0.42\times 0.31\times 0.20\\ 296(2)\\ 1.48-23.26\\ -16/14, -26/26,\\ -17/19\\ 15\ 378\\ 8273\\ SADABS\\ 773/0\\ 1.011\\ \end{array}$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{array}{r} 17 \\ C_{24}H_{18}{\rm CIN}_6{\rm O}_7{\rm Re} \\ 724.09 \\ {\rm orthorhombic} \\ P2_{12_{12_{1}}} \\ 10.7796(8) \\ 12.6297(10) \\ 19.6399(15) \\ 90 \\ 90 \\ 90 \\ 2673.8(4) \\ 4 \\ 1408 \\ 1.799 \\ {\rm Mo}\ {\rm K}\alpha, 0.710\ 73 \\ 4.699 \\ 0.26 \times 0.17 \times 0.17 \\ 100(2) \\ 1.92-27.54 \\ -13/13, -16/16, -24/25 \\ 22\ 887 \\ 1032 \\ {\rm SADABS} \\ 352/0 \\ 1.061 \\ \end{array}$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $a, deg$ $\beta, deg$ $\gamma, deg$ $\gamma, deg$ $\gamma, \delta a$ $Z$ $F(000)$ $D_{calcd}, g cm^{-3}$ radiatn $(\lambda, Å)$ $\mu, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg         min/max $h, k, l$ collcd reflcns         unique reflcns         abs         params/restraints         GOF on $F^2$ $R_i$ (on $F, l > 2\sigma(l)$ )	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0 1.044 0.0591	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P2_1/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0 1.053 0.0282	$\begin{array}{c} 10 \\ C_{46}H_{28}BF_{24}N_4O_4Re \\ 1353.73 \\ triclinic \\ P\bar{1} \\ 10.6683(17) \\ 12.405(2) \\ 19.975(3) \\ 95.593(4) \\ 95.593(4) \\ 95.245(3) \\ 99.650(3) \\ 2578.0(7) \\ 2 \\ 1320 \\ 1.744 \\ Mo K\alpha, 0.710 \\ 73 \\ 2.490 \\ 0.27 \times 0.16 \times 0.11 \\ 293(2) \\ 1.03-23.28 \\ -11/11, -10/13, \\ -22/16 \\ 11 \\ 378 \\ 7263 \\ SADABS \\ 731/0 \\ 1.030 \\ 0.0433 \\ \end{array}$	$\begin{array}{c} 11\\ C_{50}H_{37}BF_{24}N_5O_3Re\\ 1408.86\\ monoclinic\\ P2_1/n\\ 14.532(4)\\ 23.467(6)\\ 17.381(4)\\ 90\\ 103.523(5)\\ 90\\ 5763(2)\\ 4\\ 2768\\ 1.624\\ Mo\ K\alpha, 0.710\ 73\\ 2.231\\ 0.42\times 0.31\times 0.20\\ 296(2)\\ 1.48-23.26\\ -16/14, -26/26,\\ -17/19\\ 15\ 378\\ 8273\\ SADABS\\ 773/0\\ 1.011\\ 0.0464\\ \end{array}$	16 $C_{36}H_{42}N_6O_{10}Re_2$ 1091.16           monoclinic $P2_1/n$ 11.790(7)           20.368(12)           17.485(10)           90           93.392(12)           90           4192(4)           4           2120           1.729           Mo Kα, 0.710 73           5.829           0.30 × 0.14 × 0.12           296(2)           1.54-23.35           -13/12, -22/21, -18/19           18 667           6066           SADABS           488/0           1.000           0.0326	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$
param         formula         fw         cryst syst         space group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, deg$ $\gamma, mm^{-1}$ cryst size, mm         temp, K $\theta$ limits, deg         min/max $h, k, l$ collcd reflcns         unique reflcns $\alpha$ $\alpha$ $\alpha$ $\alpha$ $\alpha$ $\alpha$	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50-23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0 1.044 0.0591 0.1572	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{2_1/n}$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23-23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0 1.053 0.0282 0.0806	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	17 $C_{24}H_{18}CIN_6O_7Re$ 724.09           orthorhombic $P_{21}_{21}_{21}$ 10.7796(8)           12.6297(10)           19.6399(15)           90           90           2673.8(4)           4           1408           1.799           Mo Kα, 0.710 73           4.699           0.26 × 0.17 × 0.17           100(2)           1.92-27.54           -13/13, -16/16, -24/25           22 887           1032           SADABS           352/0           1.061           0.0232           0.0615
paramformulafwcryst systspace group $a, Å$ $b, Å$ $c, Å$ $\alpha, \deg$ $\beta, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, \deg$ $\gamma, deg$ $\gamma, Å^3$ $Z$ $F(000)$ $D_{calcd}, g cm^{-3}$ radiatn $(\lambda, Å)$ $\mu, mm^{-1}$ cryst size, mmtemp, K $\theta$ limits, degmin/max $h, k, l$ collcd reflcnsunique reflcnsabsparams/restraintsGOF on $F^2$ $R_1$ (on $F, l > 2\sigma(l)$ )wR2 (on $F^2$ , all data)max/min $\Delta o.$ e Å <sup>-3</sup>	$\frac{8}{C_{36}H_{48}N_{12}O_{14}Re_4}$ 1617.66 monoclinic P2 <sub>1</sub> /c 13.926(3) 15.559(3) 23.677(5) 90 102.265(4) 90 5013.2(19) 4 3040 2.143 Mo Kα, 0.710 73 9.697 0.13 × 0.22 × 0.49 293(2) 1.50–23.28 -12/15, -14/17, -26/26 21 799 7195 SADABS 625/0 1.044 0.0591 0.1572 6.429 and -2.628	9 $C_{11}H_8F_3N_2O_8ReS$ 571.45 monoclinic $P_{21}/n$ 9.407(5) 18.291(10) 10.210(6) 90 92.686(11) 90 1754.9(17) 4 1080 2.163 Mo K $\alpha$ , 0.710 73 7.116 0.34 × 0.15 × 0.12 296(2) 2.23–23.28 -8/10, -20/19, -11/10 7596 2518 SADABS 242/0 1.053 0.0282 0.0806 1.007 and -1.275	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$

of Hpz], 7.72 [m, 8H, H<sub>o</sub> of BAr'<sub>4</sub>], 7.56 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 7.35 [m, 3H, CH of Hpz], 6.60 [m, 3H, CH of Hpz].  ${}^{13}C{}^{1}H$  NMR (CD<sub>2</sub>Cl<sub>2</sub>):  $\delta$  193.0 [CO], 162.1 [q ( ${}^{1}J_{CB} = 49.9$  Hz), C<sup>i</sup> of BAr'<sub>4</sub>], 144.4, 134.0, [C<sup>3</sup> and C<sup>5</sup> of Hpz], 135.1 [C<sup>o</sup> of BAr'<sub>4</sub>], 129.2 [q ( ${}^{2}J_{CF} = 31.7$  Hz), C<sup>m</sup> of BAr'<sub>4</sub>], 125.0 [q ( ${}^{1}J_{CF} = 272.5$  Hz), CF<sub>3</sub> of BAr'<sub>4</sub>], 117.8 [C<sup>p</sup> of BAr'<sub>4</sub>], 109.5 [C<sup>4</sup> of Hpz]. Anal. Calcd for C<sub>44</sub>H<sub>24</sub>BF<sub>24</sub>N<sub>6</sub>O<sub>3</sub>Re: C, 39.51; H, 1.81; N, 6.28. Found: C, 39.73; H, 1.89; N, 5.96. **Synthesis of [Re(CO)<sub>3</sub>(HPhpz)<sub>3</sub>]BAr'<sub>4</sub> (14).** Compound 14 was prepared as described above for 13 from [Re(OTf)(CO)<sub>5</sub>] (0.100 g, 0.210 mmol), HPhpz (0.091 g, 0.631 mmol), and NaBAr'<sub>4</sub> (0.186 g, 0.210 mmol). Yield: 0.254 g, 77%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2039, 1935, 1925 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>3</sub>CN):  $\delta$  11.85 [s, br, 3H, NH of HPhpz], 7.71 [m, 21H, BAr'<sub>4</sub> and Ph of HPhpz], 7.52 [m, 9H, Ph and CH of HPhpz], 6.82 [s, br, 3H, CH of Hpz]. <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>3</sub>CN):  $\delta$  193.6 [CO], 162.6 [q (<sup>1</sup>J<sub>CB</sub> = 49.8 Hz), C<sup>i</sup> of BAr'<sub>4</sub>],

147.3, 145.5, [ $C^3$  and  $C^5$  of HPhpz], 134.7 [ $C^\circ$  of BAr'<sub>4</sub>], 129.1 [q ( ${}^{2}J_{CF} = 31.8 \text{ Hz}$ ),  $C^m$  of BAr'<sub>4</sub>], 124.5 [q ( ${}^{1}J_{CF} = 271.7 \text{ Hz}$ ),  $CF_3$  of BAr'<sub>4</sub>], 130.0, 129.2, 127.1, 126.7 [Ph of HPhpz], 117.3 [ $C^{\circ}$  of BAr'<sub>4</sub>], 105.5 [ $C^4$  of HPhpz]. Anal. Calcd for C<sub>62</sub>H<sub>36</sub>BF<sub>24</sub>N<sub>6</sub>O<sub>3</sub>Re: C, 47.55; H, 2.32; N, 5.37. Found: C, 47.19; H, 2.68; N, 5.51.

**Synthesis of [Re(CO)<sub>3</sub>(HIndz)<sub>3</sub>]BAr'<sub>4</sub> (15).** Compound **15** was prepared as described above for **13** from [Re(OTf)(CO)<sub>5</sub>] (0.045 g, 0.102 mmol), HIndz (0.036 g, 0.306 mmol), and NaBAr'<sub>4</sub> (0.090 g, 0.102 mmol). Yield: 0.132 g, 90%. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu$  2042, 1942 cm<sup>-1</sup> (CO). <sup>1</sup>H NMR (CD<sub>3</sub>CN):  $\delta$  11.91 [s, br, 3H, NH of HIndz], 8.06 [s, 3H, CH of HIndz], 7.81 [m, 3H, CH of HIndz], 7.72 [m, 11H, H<sub>o</sub> of BAr'<sub>4</sub> and CH of HIndz], 7.65 [m, 3H, CH of HIndz], 7.63 [m, 3H, CH of HIndz], 7.55 [m, 4H, H<sub>p</sub> of BAr'<sub>4</sub>], 7.40 [m, 3H, CH of HIndz]. Anal. Calcd for C<sub>50</sub>H<sub>30</sub>BF<sub>24</sub>N<sub>6</sub>O<sub>3</sub>Re: C, 45.20; H, 2.03; N, 5.65. Found: C, 45.02; H, 2.20; N, 5.51.

Crystal Structure Determination. General Description for Compounds 3, 4a,b, 6, 7a,b, 8–11, and 16. A suitable crystal was attached to a glass fiber and transferred to a Bruker AXS SMART 1000 diffractometer with graphite-monochromatized Mo K $\alpha$  X-radiation and a CCD area detector. One hemisphere of the reciprocal space was collected in each case. Raw frame data were integrated with the SAINT<sup>16</sup> program. The structures were solved by direct methods with SHELXTL.<sup>17</sup> An empirical absorption correction was applied with the program SADABS.<sup>18</sup> All nonhydrogen atoms were refined anisotropically. Hydrogen atoms were set in calculated positions and refined as riding atoms. Drawings and other calculations were made with SHELXTL. Crystal and refinement details are collected in Table 2.

**General Description for Compound 17.** A crystal was mounted on a CryoLoop with Paratone-N oil<sup>19</sup> and cooled to 100 K. Data were collected on a Bruker SMART APEX CCD diffractometer, and the structure was solved by direct methods and refined as indicated above. The Bruker suite of programs was used for data collection, structure solution, refinement, and graphical presentation. Crystal and refinement details are shown in Table 2.

Acknowledgment. We thank the Ministerio de Ciencia y Tecnología (Grants CTQ2006-08924 and CTQ2006-07036/ BQU) and European Union (ERG to L.R.) for support of this work. L.R. thanks the Ministerio de Educación y Ciencia for a Ramón y Cajal contract.

**Supporting Information Available:** X-ray crystallographic data for compounds **3**, **4a**,**b**, **6**, **7a**,**b**, **8**–**11**, **16**, and **17** as CIF and <sup>1</sup>H NMR titration profiles. This material is available free of charge via the Internet at http://pubs.acs.org.

#### IC0700046

<sup>(16)</sup> SAINT+. SAXI area detector integration program, version 6.02; Bruker AXS, Inc.: Madison, WI, 1999.

<sup>(17)</sup> Sheldrick, G. M. SHELXTL, An integrated system for solving, refining, and displaying crystal structures from diffraction data, version 5.1; Bruker AXS, Inc.: Madison, WI, 1998.

<sup>(18)</sup> Sheldrick, G. M. SADABS, Empirical Absorption Correction Program; University of Göttingen: Göttingen, Germany, 1997.

<sup>(19)</sup> Hamilton Research Laboratories.